Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02278328 · ClinicalTrials.gov registry record · Early Phase 1
MEG Study of Acute STX209 Effects in ASD
A Early Phase 1 study of Autism Disorder, sponsored by Timothy Roberts.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT02278328 is a Early Phase 1 study of Autism Disorder that has completed, run by Timothy Roberts. The registered enrollment target is 25 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02278328, a Early Phase 1 study of Autism Disorder, has completed, sponsored by Timothy Roberts.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-site, randomized, acute dose-response study to determine whether STX209 produces a dose-dependent significant change in MEG target parameters compared to baseline as well as compared to placebo treatment.
Conditions Studied
Interventions
- DRUG placebo
- DRUG STX209 (15mg)
- DRUG STX209 (30mg)
Study Locations (1)
Pennsylvania
- Children's Hospital of Phladelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2016-02 |
| Est. Completion | 2019-09-27 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02278328
The ClinicalTrials.gov registry entry for NCT02278328 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Timothy Roberts, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Autism Disorder appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.
NCT02278328 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02278328 about?
NCT02278328 is a clinical study titled "MEG Study of Acute STX209 Effects in ASD". This is a single-site, randomized, acute dose-response study to determine whether STX209 produces a dose-dependent significant change in MEG target parameters compared to baseline as well as compared to placebo treatment.
What is the current status of trial NCT02278328?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 25 participants. The study started on 2016-02. Estimated completion is 2019-09-27.
What conditions does trial NCT02278328 study?
This clinical trial studies the following conditions: Autism Disorder.
What interventions are being tested in trial NCT02278328?
The interventions under investigation include: placebo (DRUG), STX209 (15mg) (DRUG), STX209 (30mg) (DRUG).
Who is sponsoring clinical trial NCT02278328?
This trial is sponsored by Timothy Roberts, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02278328 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.